Iovance Biotherapeutics (IOVA) vs Relay Therapeutics (RLAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Iovance Biotherapeutics (IOVA) has outperformed Relay Therapeutics (RLAY) over the past year, gaining 486.3% versus a gain of 184.9%. Over five years, RLAY leads with a -49.0% price change compared with -50.0% for IOVA. Iovance Biotherapeutics is the larger company by market cap ($6.45 billion vs $3.91 billion), about 1.7 times the size.
Iovance Biotherapeutics converts more of its revenue into profit, with a net margin of -148.4% versus -1800.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IOVA | RLAY |
|---|---|---|
| Share price | $14.25 | $17.85 |
| Market cap | $6.45B | $3.91B |
| 1-day change | +7.07% | +2.53% |
| YTD return | +387.55% | +105.79% |
| 1-year return | +486.34% | +184.94% |
| 5-year return | -49.98% | -48.96% |
| EPS (TTM) | $-0.69 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $263.50M | $15.36M |
| Revenue growth (YoY) | +60.60% | +53.44% |
| Net income (latest FY) | $-390.98M | $-276.48M |
| Gross margin | 34.28% | — |
| Operating margin | -153.08% | -1971.59% |
| Net margin | -148.38% | -1800.58% |
| 52-week high | $15.30 | $21.27 |
| 52-week low | $1.76 | $5.85 |
| Distance from 52-week high | -6.86% | -16.08% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -10.18% | +54.51% |
| Average volume | 17.82M | 2.80M |
| Shares outstanding | 452.97M | 219.14M |
| Employees | 975 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IOVA has outperformed RLAY by 301.4 percentage points over the past year.
- Iovance Biotherapeutics is more profitable, keeping -148.4 cents of every revenue dollar as net income versus -1800.6 cents for Relay Therapeutics.
- Iovance Biotherapeutics grew revenue faster in its latest fiscal year (+60.60% vs +53.44%).
About Iovance Biotherapeutics
IOVA stock →Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees
About Relay Therapeutics
RLAY stock →Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 202 employees
IOVA vs RLAY FAQ
Which is bigger, Iovance Biotherapeutics or Relay Therapeutics?
Iovance Biotherapeutics (IOVA) is larger, with a market capitalization of $6.45B compared with $3.91B for Relay Therapeutics (RLAY).
Which stock has performed better over the past year, IOVA or RLAY?
IOVA returned +486.34% over the past 12 months, compared with +184.94% for RLAY (price return, excluding dividends). Past performance does not predict future results.
Are Iovance Biotherapeutics and Relay Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.